Results 201 to 210 of about 14,501,441 (297)

Thermosensory reconfiguration of the auxin transcriptional pathway to drive root cell growth. [PDF]

Nat Commun
Borniego MB, Pereyra ME, Sageman-Furnas K, Rossi AH, Wilkinson EG, Strader LC, Casal JJ.   +6 more
europepmc   +1 more source

Biochemistry of protein prenylation.

Journal of Lipid Research, 1992
PJ Casey
doaj   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Gene overexpression reduces inhibitory metabolites to enhance CHO cell growth and IgG1 production. [PDF]

NPJ Syst Biol Appl
Hoang D, Kuang B, Wang Z, Liang G, Yoon S.   +4 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Cell Growth and Division Shape mRNA–Protein Correlations

Biswas K, Sheinman M, Sepúlveda LA, Golding I, Amir A.   +4 more
europepmc   +1 more source

The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth. [PDF]

Commun Biol
Strunk J, Hüppner A, Sial M, Plath M, Sheriff MB, Wagner S, Freitag K, Mikuličić S, Döring T, Bopp T, Klein M, Rajalingam K, Harms G, Marini F, Nedwed AS, Hankeln T, Osterhof C, Schneider MA, Henrich A, Nubbemeyer A, Suchan M, Brill S, Perkovic M, Schrörs B, Kreiter S, Kölsch A, Diken M, Florin L.   +27 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Inhibition of CT26 Colon Cancer Cell Growth by Green-Synthesised Silver Nanoparticles-Mediated <i>Strobilanthes crispus</i> Extract. [PDF]

Malays J Med Sci
Abd Ghafar SA, Hairil Anuar AH, Salihuddin MAH, Mohamad Hanafiah R.   +3 more
europepmc   +1 more source